News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chroma Therapeutics to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797



11/30/2007 7:01:11 AM

OXFORD, England, Nov. 30 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:

The ASH posters will be available at the company's website, www.chromatherapeutics.com following the above presentations.

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at www.chromatherapeutics.com.

CONTACT: Ian Nicholson, Chief Executive Officer, or Richard Bungay, Chief
Financial Officer, +44-0-1235-829120, both of Chroma Therapeutics Limited;
or Jon Coles or Justine McIlroy, +44-0-20-7404-5959, both of Brunswick, for
Chroma Therapeutics Limited

Web site: http://www.chromatherapeutics.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES